Search Results for "Colchicine And Rivaroxaban"

18:50 EST 28th November 2015 | BioPortfolio

Matching Channels


Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

VTE in Primary Care: Patient Management With Rivaroxaban

Get guidance on the practical use of rivaroxaban for the treatment of patients with VTE. British Journal of Cardiology

Japan approves rivaroxaban as treatment for thrombosis

Japan's Ministry of Health, Labor and Welfare has approved rivaroxaban, or Xarelto, for the secondary prevention and treatmen -More- 

Uninterrupted Rivaroxaban Feasible in AF Ablations, in Study

Event rates were low, but no major bleeding complications and no thromboembolic events occurred in the ablation group that had rivaroxaban maintained during the AF procedure. Heartwire from Meds...

ROCKET-AF: Rivaroxaban, Warfarin Similar for AF Plus Diabetes

More findings show similar safety and efficacy rates between the two treatments, whether or not AF patients also have diabetes, suggesting rivaroxaban may be a feasible alternative. Heartwire fr...

Low bleeding and stroke rates in AF patients given rivaroxaban for stroke prevention

(European Society of Cardiology) Atrial fibrillation (AF) patients treated with rivaroxaban for stroke prevention have low rates of bleeding and stroke, reveals real-world data from the XANTUS study p...

EU OKs rivaroxaban testing solution from Instrumentation Laboratory

HemosIL, a solution developed by Instrumentation Laboratory to test for rivaroxaban, has obtained CE mark approval from Europ -More- 

Janssen, Bayer initiate anticoagulant rivaroxaban trials

Janssen Pharmaceuticals and its development partner, Bayer HealthCare, have initiated CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patie...

Could Old Gout Drug Offer New CV Benefits? (CME/CE)

(MedPage Today) -- Colchicine use was associated with fewer cardiovascular events and lower all-cause mortality

Matching PubMed Articles

Rivaroxaban does not impair fracture healing in a rat femur fracture model: an experimental study.

The prescription of the oral anticoagulant rivaroxaban to prevent thromboembolic episodes associated with orthopaedic surgery has dramatically increased since it was introduced. Rivaroxaban is beeing ...

Fatal intracerebral bleeding under rivaroxaban.

Rivaroxaban is a factor-Xa-inhibitor which has been shown to be non-inferior to the vitamin-K-antagonist (VKA) warfarin in atrial fibrillation patients. In the manufacturer-sponsored trial, the rate o...

Of men and meals.

Rivaroxaban is increasingly used to treat patients with acute venous thromboembolism (VTE), a potentially life-threatening condition. Since absorption of rivaroxaban decreases from nearly 100% to 66% ...

Association of Rivaroxaban Anticoagulation and Spontaneous Vitreous Hemorrhage.

Rivaroxaban is an anticoagulant prescribed for the management of atrial fibrillation. We describe a correlation between rivaroxaban and spontaneous vitreous hemorrhage.

In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate.

Four-factor prothrombin complex concentrate (PCC) 50 iu/kg is able to swiftly restore haemostatic parameters in healthy subjects on rivaroxaban. We hypothesized that lower dosages of PCC may be suffic...

Search Whole site using Google


Advertisement Advertisement